Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Communication with company.

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Oct 31, 2023 3:54pm

231 Views

Post# 35709894

RE:RE:RE:Communication with company.

There is usually a communication black out within a certain period of quarter reports.
it does not mean they can't issue news, if appropriate.
They are however restricted in emails & phone calls.
Also, getting an answer totally depends on your questions.
Anything what so ever involving business development, or anything trial based that is not public knowledge will not be discussed.
That holds true for any company.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project